Zai Lab Ltd (ZLAB) stock
Close on Nov 11, 2026Market cap $4.10BP/E –Yield –
Zai Lab Ltd grew revenue 0.0% to $441.73M over the twelve months to Sep 30, 2026. Free cash flow was -$163.34M. At the latest close the market valued the company at $4.10B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.10B
- P/E ratio
- –
- Price to sales
- 9.29
- Price to book
- 7.28
- Dividend yield
- –
- Free cash flow yield
- -3.98%
Fundamentals
- Revenue
- $441.73M
- Net income
- -$198.39M
- EPS, diluted
- -$0.19
- Free cash flow
- -$163.34M
- Book value per share
- $0.50
- Diluted shares
- 1.12B
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $26.43
- Open
- $25.93
- Day's range
- $25.30 – $26.50
- Volume
- 920,477
- Average volume (20 days)
- 1,294,196
- Beta (5 years)
- 1.11
- 52-week range
- $15.96 – $29.02
- RSI (14 days)
- 60.8
- Volatility (1 year)
- 52.1%
- Relative volume
- 0.90×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZLAB | S&P 500 | Difference | ZLAB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +5.7% | -2.4% | +8.1 pts | ||
| 3 months | +1.6% | -1.2% | +2.8 pts | ||
| Year to date | +49.8% | +12.3% | +37.5 pts | ||
| 1 year | +20.1% | +12.4% | +7.6 pts | ||
| 3 years | -6.2% | +78.8% | −85.0 pts | -2.1% | +21.4% |
| 5 years | -69.0% | +75.2% | −144.2 pts | -20.9% | +11.9% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zai Lab filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Results
- Results
About Zai Lab
Pharmaceutical Preparations
Zai Lab is a commercial-stage biopharmaceutical company that develops and commercializes therapies for oncology, autoimmune disorders, neuroscience, and infectious diseases. Its commercial portfolio features licensed therapies including ZEJULA for ovarian cancer, VYVGART and VYVGART Hytrulo for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, NUZYRA for pneumonia and skin infections, and OPTUNE for glioblastoma. The company also markets QINLOCK for gastrointestinal stromal tumors, XACDURO for hospital-acquired bacterial infections, and AUGTYRO for solid tumors and non-small cell lung cancer. Its customers include medical centers, distributors, and adult patients requiring specialized treatments.
Company profile, executives and historyZai Lab stock: common questions
What is Zai Lab's stock price?
ZLAB closed at $26.42 on Nov 11, 2026, down 0.04% on the day. Over the past 52 weeks it traded between $15.96 and $29.02.
What is Zai Lab's market cap?
Zai Lab was worth $4.10B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ZLAB's P/E ratio?
Zai Lab lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
How much revenue does Zai Lab make?
Zai Lab reported revenue of $441.73M for the twelve months to Sep 30, 2026, up 0.0% from a year earlier.
Does Zai Lab pay a dividend?
No. Zai Lab has not paid a cash dividend over the last twelve months.
When does Zai Lab report earnings next?
Zai Lab is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ZLAB stock performed over the past year?
Including dividends, ZLAB returned +20.1% over the past year, against +12.4% for the S&P 500.
Who are Zai Lab's competitors?
Companies most similar to Zai Lab by business, industry and size include HCM, AAPG, SNDX, ZYME, ARQT.
See a number that looks wrong?